217 related articles for article (PubMed ID: 31541032)
1. Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment-Related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis.
de Zwart PL; van Dijken BRJ; Holtman GA; Stormezand GN; Dierckx RAJO; Jan van Laar P; van der Hoorn A
J Nucl Med; 2020 Apr; 61(4):498-504. PubMed ID: 31541032
[TBL] [Abstract][Full Text] [Related]
2. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and grading accuracy of
Xiao J; Jin Y; Nie J; Chen F; Ma X
BMC Cancer; 2019 Aug; 19(1):767. PubMed ID: 31382920
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
[TBL] [Abstract][Full Text] [Related]
5. Performance of 18F-FDG, 11C-Methionine, and 18F-FET PET for Glioma Grading: A Meta-analysis.
Katsanos AH; Alexiou GA; Fotopoulos AD; Jabbour P; Kyritsis AP; Sioka C
Clin Nucl Med; 2019 Nov; 44(11):864-869. PubMed ID: 31205150
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of
He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
[TBL] [Abstract][Full Text] [Related]
7. Comparison of
Unterrainer M; Fleischmann DF; Diekmann C; Vomacka L; Lindner S; Vettermann F; Brendel M; Wenter V; Ertl-Wagner B; Herms J; Wetzel C; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):580-590. PubMed ID: 30244386
[TBL] [Abstract][Full Text] [Related]
8. Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma.
Galldiks N; Stoffels G; Ruge MI; Rapp M; Sabel M; Reifenberger G; Erdem Z; Shah NJ; Fink GR; Coenen HH; Langen KJ
J Nucl Med; 2013 Dec; 54(12):2046-54. PubMed ID: 24159047
[TBL] [Abstract][Full Text] [Related]
9. Application of Artificial Intelligence in Oncologic Molecular PET-Imaging: A Narrative Review on Beyond [
Eisazadeh R; Shahbazi-Akbari M; Mirshahvalad SA; Pirich C; Beheshti M
Semin Nucl Med; 2024 Mar; 54(2):293-301. PubMed ID: 38331629
[TBL] [Abstract][Full Text] [Related]
10. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.
Dunet V; Pomoni A; Hottinger A; Nicod-Lalonde M; Prior JO
Neuro Oncol; 2016 Mar; 18(3):426-34. PubMed ID: 26243791
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
[TBL] [Abstract][Full Text] [Related]
12. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma.
Galldiks N; Stoffels G; Filss C; Rapp M; Blau T; Tscherpel C; Ceccon G; Dunkl V; Weinzierl M; Stoffel M; Sabel M; Fink GR; Shah NJ; Langen KJ
Neuro Oncol; 2015 Sep; 17(9):1293-300. PubMed ID: 26008606
[TBL] [Abstract][Full Text] [Related]
13. The role of [
Roach JR; Plaha P; McGowan DR; Higgins GS
J Neurooncol; 2022 Dec; 160(3):577-589. PubMed ID: 36434486
[TBL] [Abstract][Full Text] [Related]
14.
Maurer GD; Brucker DP; Stoffels G; Filipski K; Filss CP; Mottaghy FM; Galldiks N; Steinbach JP; Hattingen E; Langen KJ
J Nucl Med; 2020 Apr; 61(4):505-511. PubMed ID: 31519802
[TBL] [Abstract][Full Text] [Related]
15. Differentiating high-grade glioma progression from treatment-related changes with dynamic [
Rozenblum L; Zaragori T; Tran S; Morales-Martinez A; Taillandier L; Blonski M; Rech F; Galanaud D; Kas A; Verger A
Eur Radiol; 2023 Apr; 33(4):2548-2560. PubMed ID: 36367578
[TBL] [Abstract][Full Text] [Related]
16. Comparison of
Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2257-2265. PubMed ID: 28831534
[TBL] [Abstract][Full Text] [Related]
17. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
[TBL] [Abstract][Full Text] [Related]
18. Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis.
Dunet V; Rossier C; Buck A; Stupp R; Prior JO
J Nucl Med; 2012 Feb; 53(2):207-14. PubMed ID: 22302961
[TBL] [Abstract][Full Text] [Related]
19. Treatment-Related Uptake of
Geisler S; Stegmayr C; Niemitz N; Lohmann P; Rapp M; Stoffels G; Willuweit A; Galldiks N; Filss C; Sabel MC; Coenen HH; Shah NJ; Langen KJ
J Nucl Med; 2019 Oct; 60(10):1373-1379. PubMed ID: 30850492
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis.
Cui M; Zorrilla-Veloz RI; Hu J; Guan B; Ma X
Front Neurol; 2021; 12():671867. PubMed ID: 34093419
[No Abstract] [Full Text] [Related]
[Next] [New Search]
